Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,285
datasets available to search
ShareScore release 0.9.0
Dataset results
2,285 results for “T-cells”
Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
ClinicalTrials.gov study NCT00030589. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effect of Fasting and Refeeding on T-cell Fate
ClinicalTrials.gov study NCT02719899. IPD Sharing: Not stated. Countries: 1. Publications: 4.
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ClinicalTrials.gov study NCT05938725. IPD Sharing: NO. Countries: 1. Publications: 2.
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
ClinicalTrials.gov study NCT02802098. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
ClinicalTrials.gov study NCT01280526. IPD Sharing: Not stated. Countries: 1. Publications: 1.
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma
ClinicalTrials.gov study NCT00669812. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Newly-diagnosed Pediatric T-cell ALL Protocol
ClinicalTrials.gov study NCT06855810. IPD Sharing: YES. Countries: 2. Publications: 35.
Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia
ClinicalTrials.gov study NCT03989466. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
ClinicalTrials.gov study NCT05414162. IPD Sharing: UNDECIDED. Countries: 1. Publications: 23.
A Study of Familial and Genetic Aspects of Adult T-Cell: Leukemia/Lymphoma , Tropical Spastic Paraparesis, and Infective Dermatitis
ClinicalTrials.gov study NCT00340821. IPD Sharing: Not stated. Countries: 1. Publications: 3.
A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Usin
ClinicalTrials.gov study NCT02007356. IPD Sharing: NO. Countries: 1. Publications: 1.
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)
ClinicalTrials.gov study NCT00611208. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
ClinicalTrials.gov study NCT04480099. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
ClinicalTrials.gov study NCT03502577. IPD Sharing: NO. Countries: 1. Publications: 2.
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
ClinicalTrials.gov study NCT02779439. IPD Sharing: NO. Countries: 1. Publications: 1.
Timing of blood sample processing affects the transcriptomic and epigenomic profiles in CD4+ T-cells of atopic subjects
Open the record for dataset details and reuse information.
Systematic profiling of full-length immunoglobulin and T-cell receptor repertoire diversity in rhesus macaque through long read transcriptome sequencing
<p>Using long read sequencing, we sequenced four Indian-origin rhesus macaque tissues. From raw full-length, non-chimeric circular consensus sequencing (CCS) reads, we obtained high quality, full-length sequences for over 6,000 unique immunoglobulin and T-cell receptor transcripts, without the need for sequence assembly.</p>
Data from: A single 17D Yellow Fever vaccination provides lifelong immunity; characterization of Yellow-Fever-specific neutralizing antibody and T-cell responses after vaccination
Introduction: Prompted by recent amendments of Yellow Fever (YF) vaccination guidelines from boost to single vaccination strategy and the paucity of clinical data to support this adjustment, we used the profile of the YF-specific CD8+ T-cell subset profiles after primary vaccination and neutralizing antibodies as a proxy for potentially longer lasting immunity. Methods and Findings: PBMCs and serum were collected in six individuals on days 0, 3, 5, 12, 28 and 180, and in 99 individuals >10 years after YF-vaccination. Phenotypic characteristics of YF- tetramer+ CD8+ T-cells were determined using class I tetramers. Antibody responses were measured using a standardized plaque reduction neutralization test (PRNT). Also, characteristics of YF-tetramer positive CD8+ T-cells were compared between individuals who had received a primary- and a booster vaccination. YF-tetramer+ CD8+ T-cells were detectable on day 12 (median tetramer+ cells as percentage of CD8+ T-cells 0.2%, range 0.07–3.1%). On day 180, these cells were still present (median 0.06%, range 0.02–0.78%). The phenotype of YF-tetramer positive CD8+ T-cells shifted from acute phase effector cells on day 12, to late differentiated or effector memory phenotype (CD45RA-/+CD27-) on day 28. Two subsets of YF-tetramer positive T-cells (CD45RA+CD27- and CD45RA+CD27+) persisted until day 180. Within all phenotypic subsets, the T-bet: Eomes ratio tended to be high on day 28 after vaccination and shifted towards predominant Eomes expression on day 180 (median 6.0 (day 28) vs. 2.2 (day 180) p = 0.0625), suggestive of imprinting compatible with long-lived memory properties. YF-tetramer positive CD8+ T-cells were detectable up to 18 years post vaccination, YF-specific antibodies were detectable up to 40 years after single vaccination. Booster vaccination did not increase titers of YF-specific antibodies (mean 12.5 vs. 13.1, p = 0.583), nor induce frequencies or alter phenotypes of YF-tetramer+ CD8+ T-cells. Conclusion: The presence of a functionally competent YF-specific memory T-cell pool 18 years and sufficient titers of neutralizing antibodies 35–40 years after first vaccination suggest that single vaccination may be sufficient to provide long-term immunity.
mTORC1 in thymic epithelial cells is critical for thymopoiesis, T-cell generation, and temporal control of gdT17 development and TCRg/d recombination
<p>FCS Files for Fig 1 to Fig 11</p>
Pep-TCRNet: Prediction of Multi-Class Peptides by T-cell Receptor Sequences with Deep Learning
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.